

ASX Announcement

MD Anderson Cancer Center Researchers Publish AML Preclinical Study on Bisantrene Drug Combinations

- Researchers from the MD Anderson Cancer Center in Texas have identified Bisantrene drug combinations with superior efficacy in AML cells
- This work showed synergy for Bisantrene when used in combination with standard-of-care AML drugs
- This research supports Race's Phase II relapsed / refractory AML clinical trial expected to begin at the Chaim Sheba Medical Center, Israel in Q2 CY2021

10 May 2021 – Race Oncology Limited ("Race") is pleased to announce a team of researchers, led by Professor Borje Andersson and Associate Professor Ben Valdez of the MD Anderson Cancer Center (Texas, USA), have identified a number of clinically translatable drug combinations that showed synergy with Bisantrene when tested in Acute Myeloid Leukaemia (AML) cells.

This study¹, sponsored by Race, has been published in the *Journal of Clinical & Experimental Oncology* and is entitled "*Synergism of the Anthracene-Derivative Anti-Cancer Agent Bisantrene with Nucleoside Analogs and A Bcl-2 Inhibitor in Acute Myeloid Leukemia Cells*".

The MD Anderson team identified that Bisantrene, when used in combination with the standard-of-care AML drugs cytarabine, cladribine, fludarabine, clofarabine and/or ABT199 (Venclexta) showed enhanced activation of apoptosis (cell killing) in AML cells. Combinations of three or more of these drugs with Bisantrene showed additional synergism and effective cell killing at drug concentrations far below that observed when the drugs were used on their own.

Race Chief Scientific Officer, Dr Daniel Tillett said: *"This work provides the preclinical data to support our upcoming Phase II relapsed / refractory AML trial at the Chaim Sheba Medical Center, where patients will be treated with Bisantrene in combination with the nucleoside analogs, clofarabine and fludarabine. This trial is scheduled to begin in Q2 CY2021. We are extremely excited about being able to quickly translate this work from the lab into the clinic, where it has the potential to help AML patients in need."*

1. Valdez BC, Murray D, Li Y, Liu Y, Nieto Y, et al., (2021) Synergism of the Anthracene-Derivative Anti-Cancer Agent Bisantrene with Nucleoside Analogs and A Bcl-2 Inhibitor in Acute Myeloid Leukemia Cells. *J Clin Exp Oncol* 10:4.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

Bisantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers. The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

Race is pursuing outsized commercial returns for shareholders via its 'Three Pillar' strategy for the clinical development of Bisantrene.

See more at www.raceoncology.com.

Release authorised by:

Phil Lynch, CEO/MD on behalf
of the Race Board of Directors
phillip.lynch@raceoncology.com

Media contact:

Jane Lowe
+61 411 117 774
jane.lowe@irdepartment.com.au